Invokana 300 mg film-coated tablets clinical trials
3 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic confirmatory (Phase III)
Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus
This study looks at how certain diabetes medications, called SGLT2 inhibitors, might affect the build-up of fatty deposits (atherosclerosis) in the heart's arteries after a heart attack. It aims to see if these medicines can slow down or stop this build-up in people with diabetes.
For: Myocardial Infarction · diabetes mellitusItaly - Ongoing, recruitingTherapeutic use (Phase IV)
Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
This study is looking at how well different diabetes medicines, like Invokana and Forxiga, work and how safe they are for older people with type 2 diabetes. The main goal is to see if these medicines help control blood sugar without causing dangerously low levels.
For: Type 2 diabetes mellitusItaly - AuthorisedTherapeutic use (Phase IV)
CANIDIAP; CANagliflozin In DIAlysis Patients
This study is looking at how a kidney medicine called canagliflozin (known as Invokana) works in people on dialysis. We want to see how much of the medicine reaches certain parts of the body, which helps us understand if it's working as intended.
For: Chronic Kidney diseaseNetherlands